Stereoselective metabolic activation of α -hydroxy-N-desmethyltamoxifen: The R-isomer forms more DNA adducts in rat liver cells

Chemical Research in Toxicology

Volumn 17, Issue 5, 2004, Pages 697-701

  Osborne, Martin R ^a   Hewer, Alan ^a   Phillips, David H ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXY N NORTAMOXIFEN; HYDROXYTAMOXIFEN; NORTAMOXIFEN; PHOSPHORUS 32; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DNA ADDUCT; DRUG CONJUGATION; DRUG HYDROLYSIS; DRUG STRUCTURE; ENANTIOMER; LIVER CELL; METABOLIC ACTIVATION; NONHUMAN; RAT; STEREOCHEMISTRY;

ANIMALS; DNA ADDUCTS; HEPATOCYTES; HYDROLYSIS; LIVER; RATS; STEREOISOMERISM; TAMOXIFEN;

ANIMALIA;

EID: 2442652806     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx049957w     Document Type: Article

References (30)

1. Phillips, D. H. (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis 22, 839-849.
2. Osborne, M. R. (1999) Genotoxicity of tamoxifen and other antiestrogens. Recent Res. Dev. Cancer 1, 69-81.
3. White, I. N. H. (1999) The tamoxifen dilemma. Carcinogenesis 20, 1153-1160.
4. Boocock, D. J., Brown, K., Gibbs, A. H., Sanchez, E., Turteltaub, K. W., and White, I. N. (2002) Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23, 1897-1901.
5. Coller, J. K., Krebsfaenger, N., Klein, K., Wolbold, R., Nussler, A., Neuhaus, P., Zanger, U. M., Eichelbaum, M., and Murdter, T. E. (2004) Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. Br. J. Clin. Pharmacol. 57, 105-111.
6. Davis, W., Venitt, S., and Phillips, D. H. (1998) The metabolic activation of tamoxifen and α-hydroxytamoxifen to DNA binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis 19, 861-866.
7. Glatt, H., Davis, W., Meinl, W., Hermersdörfer, H., Venitt, S., and Phillips, D. H. (1998) Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis 19, 1709-1713.
8. Shibutani, S., Dasaradhi, L., Terashima, I., Banoglu, E., and Duffel, M. W. (1998) Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res. 58, 647-653.
9. Poirier, M. C., and Schild, L. J. (2003) The genotoxicity of tamoxifen: extent and consequences, Kona, Hawaii, January 23, 2003. Mutagenesis 18, 395-399.
10. 32p-Postlabeled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16, 1651-1654.
11. Schild, L. J., Divi, R. L., Beland, F. A., Churchwell, M. I., Doerge, D. R., Gamboa da Costa, G., Marques, M. M., and Poirier, M. C. (2003) Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res. 63, 5999-6003.
12. Shibutani, S., Suzuki, N., Laxmi, Y. R., Schild, L. J., Divi, R. L., Grollman, A. P., and Poirier, M. C. (2003) Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res. 63, 4402-4406.
13. Carmichael, P. L., Ugwumadu, A. H. N., Neven, P., Hewer, A., Poon, G. K., and Phillips, D. H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 56, 1475-1479.
14. Carmichael, P. L., Sardar, S., Crooks, N., Neven, P., Van Hoof, I., Ugwumadu, A., Bourne, T., Tomas, E., Hellberg, P., Hewer, A. J., and Phillips, D. H. (1999) Lack of evidence from HPLC 32P-post-labeling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis 20, 339-342.
15. Shibutani, S., Ravindernath, A., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., and Pearl, M. L. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21, 1461-1467.
16. Martin, E. A., Brown, K., Gaskell, M., Al-Azzawi, F., Garner, R. C., Boocock, D. J., Mattock, E., Pring, D. W., Dingley, K., Turteltaub, K. W., Smith, L. L., and White, I. N. (2003) Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 63, 8461-8465.
17. White, I. N. (2001) Anti-oestrogenic drugs and endometrial cancers. Toxicol. Lett. 120, 21-29.
18. Rajaniemi, H., Rasanen, I., Koivisto, P., Peltonen, K., and Hemminki, K. (1999) Identification of the major tamoxifen-DNA adducts in rat liver by mass spectroscopy. Carcinogenesis 20, 305-309.
19. Phillips, D. H., Hewer, A., Horton, M. N., Cole, K. J., Carmichael, P. L., Davis, W., and Osborne, M. R. (1999) N-Demethylation accompanies α-hydroxylation in the metabolic activation of tamoxifen in rat liver cells. Carcinogenesis 20, 2003-2009.
20. Brown, K., Heydon, R. T., Jukes, R., White, I. N. H., and Martin, E. A. (1999) Further characterisation of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen. Carcinogenesis 20, 2011-2016.
21. Gamboa da Costa, G., Hamilton, L. P., Beland, F. A., and Marques, M. M. (2000) Characterization of the major DNA adduct formed by alpha-hydroxy-N-desmethyltamoxifen in vitro and in vivo. Chem. Res. Toxicol. 13, 200-207.
22. Osborne, M. R., Hewer, A., and Phillips, D. H. (2001) Resolution of alpha-hydroxytamoxifen; R-isomer forms more DNA adducts in rat liver cells. Chem. Res. Toxicol. 14, 888-893.
23. Kitagawa, M., Ravindernath, A., Suzuki, N., Rieger, R., Terashima, I., Umemoto, A., and Shibutani, S. (2000) Identification of tamoxifen-DNA adducts induced by alpha-acetoxy-N-desmethyl-tamoxifen. Chem. Res. Toxicol. 13, 761-769.
24. Osborne, M. R., Hewer, A., Hardcastle, I. R., Carmichael, P. L., and Phillips, D. H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56, 66-71.
25. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., and Poon, G. K. (1994) α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res. 54, 5518-5522.
26. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., Hardcastle, I. R., Poon, G. K., Keogh, A., and Strain, A. J. (1996) Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis 17, 88-94.
27. Foster, A. B., Jarman, M., Leung, O.-T., McCague, R., Leclercq, G., and Devleeschouwer, N. (1985) Hydroxy derivatives of tamoxifen. J. Med. Chem. 28, 1491-1497.
28. Gamboa da Costa, G., McDaniel-Hamilton, L. P., Heflich, R. H., Marques, M. M., and Beland, F. A. (2001) DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 22, 1307-1315.
29. Poon, G. K., Walter, B., Lonning, P. E., Horton, M. N., and McCague, R. (1995) Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Dispos. 23, 377-382.
30. Langan-Fahey, S. M., Tormey, D. C., and Jordan, V. C. (1990) Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur. J. Cancer 26, 883-888.